Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
Vistagen Therapeutics Inc (NASDAQ:VTGN) shares were nearly cut in half Thursday following adverse results from a Phase 2 study evaluating its treatment-resistant depression (TRD) drug candidate.
What Happened
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
Vistagen, a thinly traded nanocap, said Thursday after the market open that topline results from an exploratory Phase 2 study of its investigational drug AV-101 did not demonstrate significant difference from placebo on the primary outcome measure.
The drug, which is being evaluated as a monotherapy in patients with TRD, was studied for the change from baseline in the Hamilton Depression Rating Scale total score.
On the safety front, the company said that, consistent with Phase 1 studies, AV-101 was very well tolerated, with no ketamine-like psychological side effects; safety concerns; or treatment-related adverse events.
AV-101 is an oral NMDA receptor glycine site antagonist with the potential to be a treatment for multiple CNS indications with a high unmet need.
Why It's Important
Major Depressive Disorder, or MDD, becomes TRD when affected individuals have not responded to at least two different treatments with antidepressants in a moderate-to-severe depressive episode.
FREE REPORT: How To Learn Options Trading Fast
In this special report, you will learn the four best strategies for trading options, how to stay safe as a complete beginner, a 411% trade case study, PLUS how to access two new potential winning options trades starting today.Claim Your Free Report Here.
About one-third of the people with MDD who do not find relief with antidepressants are said to have TRD.
Incidentally, Johnson & Johnson (NYSE:JNJ)'s Janssen unit won FDA approval for its Spravato — chemically esketamine CIII nasal spray and a drug belonging to the same class as Vistagen's — in early March.
What's Next
Vistagen is also evaluating AV-101 in a study dubbed ELEVATE as an adjunctive therapy in a significantly different population of MDD patients — those whose current depressive episode is less than two years in duration.
The pipeline asset has been granted Fast Track Designation for development as both as an adjunctive treatment for MDD and as a non-opioid treatment for neuropathic pain.
At last check, Vistagen shares were plummeting 44.91 percent to 58 cents on roughly 11 times their average volume.
Related Links:
Attention Biotech Investors: Mark Your Calendar For These May PDUFA Dates
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.